Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eDREAM Study: GAL-101 in Non-foveal Geographic Atrophy
NCT06659549Phase 2Recruiting
- Sponsor
- Galimedix Therapeutics
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of gal-101 in geographic atrophy (GA), sponsored by Galimedix Therapeutics. Started Jan 2025; status: recruiting.
02
Drugs
gal-101
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06659549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659549.